Effect of Early Prophylactic High-Dose Recombinant Human Erythropoietin in Very Preterm Infants on Neurodevelopmental Outcome at 2 Years: A Randomized Clinical Trial

Autor: Natalucci, Giancarlo, Latal, Beatrice, Koller, Brigitte Marie, Ruegger, Christoph Emanuel, Sick, Beate, Held, Leonhard, Bucher, Hans Ulrich, Fauchère, Jean-Claude, Pfister, Riccardo, The Swiss EPO Neuroprotection Trial Group

Publikováno v: JAMA (Journal of the American Medical Association), Vol. 315, No 19 (2016) pp. 2079-85

Importance Very preterm infants are at risk of developing encephalopathy of prematurity and long-term neurodevelopmental delay. Erythropoietin treatment is neuroprotective in animal experimental and human clinical studies. Objective To determine whet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::535a26dee6115b75e780cd3d0bb1126a
https://pubmed.ncbi.nlm.nih.gov/27187300

STEPPING UP VERSUS STANDARD DOSES OF ERYTHROPOIETIN IN PRETERM INFANTS: A Randomized Controlled Trial

Autor: Pierre Wacker, Bernadette Mermillod, Laurence Cingria, Fabienne Gumy-Pause, Michel Berner, Hulya Ozsahin

Publikováno v: Pediatric Hematology & Oncology, Vol. 22, No 8 (2005) pp. 667-78

In this study, it is hypothesized that a planned increase in the dose of recombinant human erythropoietin (rh-EPO) can prevent transfusion in very low birth weight infants. Two different regimens of rh-EPO were administrated, one consisting in increa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce9e785f3dcb0178fb58d9650e61f1be
https://doi.org/10.1080/08880010500278715

Alterations in body weight, breaking strength, and wound healing in Wistar rats treated pre- and postoperatively with erythropoietin or granulocyte macrophage–colony stimulating factor: Evidence of a previously unknown anabolic effect of erythropoietin?

Autor: A.M. Kappas, M. S. Fatouros, E. P. Mylonakis, G.N. Dalekos, G. Vekinis

Publikováno v: Journal of Laboratory and Clinical Medicine. 133:253-259

Several growth factors, such as growth hormone and insulin-like growth factor-1, have been used to reverse the high rate of catabolism observed either after an operation or during serious illness. We conducted a pilot study in Wistar rats in an attem

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11d62102c4d43af77a14036b97d646d6
https://doi.org/10.1016/s0022-2143(99)90081-1

Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C

Autor: F, Stickel, B, Helbling, M, Heim, A, Geier, C, Hirschi, B, Terziroli, K, Wehr, A, De Gottardi, F, Negro, T, Gerlach

Publikováno v: Journal of Viral Hepatitis, Vol. 19, No 2 (2012) pp. 77-87

Combined pegylated interferon (PegIFN) and ribavirin represents the standard therapy for patients with chronic hepatitis C (CHC), which allows for sustained viral response (SVR) in up to 90% of patients depending on certain viral and host factors. Cl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::938680bf04e481a89ae00f2f78c3641f
https://archive-ouverte.unige.ch/unige:27538

Dose reduction of epoetin-alpha in the prevention of chemotherapy-induced anaemia

Autor: Christian Monnerat, M. Pless, Richard Hermann, Beat Biedermann, Emilie Müller, Serge Leyvraz, François Luthi

Publikováno v: Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer, vol. 18, no. 12, pp. 1515-1520

INTRODUCTION: Anaemia during chemotherapy is often left untreated. Erythropoiesis-stimulating agents are frequently used to treat overt anaemia. Their prophylactic use, however, remains controversial and raises concerns about cost-effectiveness. Ther

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16bb786ed970ff321289662e964325d1
https://serval.unil.ch/notice/serval:BIB_2EA885FAEBB0